Intranasal Immunization with BCG in a Mouse Model
JoVE Encyclopedia of Experiments
Immunology
0 views • 2:16 min • July 8th, 2025
Loading...
Overview
This study investigates the immune response generated by intranasal administration of a live-attenuated BCG strain of Mycobacterium bovis in mice. The research focuses on the activation of T cells and B cells, which are crucial for long-term immunity against mycobacterial infections.
Key Study Components
Area of Science
- Immunology
- Microbiology
- Infectious Diseases
Background
- Mycobacterium bovis is a pathogen that can cause disease in humans.
- BCG vaccination is known to provide some protection against tuberculosis.
- Understanding the immune response to BCG can help improve vaccination strategies.
- Effector T cells and B cells play a significant role in the immune defense.
Purpose of Study
- To evaluate the immune response elicited by BCG vaccination in mice.
- To assess the activation of resident memory T cells in the lungs.
- To determine the effectiveness of the vaccination against virulent mycobacteria.
Methods Used
- Intranasal administration of BCG strain to anesthetized mice.
- Monitoring the generation of effector T cells and B cells.
- Challenge with virulent Mycobacterium tuberculosis to assess immunity.
- Measurement of cytokine release and antibody production.
Main Results
- BCG vaccination led to the generation of effector T and B cells.
- Activated T RM cells were found in lung tissue post-vaccination.
- Effector B cells produced antibodies that enhanced mycobacterial clearance.
- The study demonstrated successful immunization against virulent strains.
Conclusions
- Intranasal BCG vaccination effectively primes the immune system.
- Resident memory T cells play a crucial role in long-term immunity.
- This approach may inform future tuberculosis vaccination strategies.
Frequently Asked Questions
What is the significance of using BCG in this study?
BCG is a live-attenuated vaccine that stimulates an immune response, making it a valuable tool for studying tuberculosis immunity.
How does intranasal administration benefit vaccination?
Intranasal administration targets the respiratory mucosa, which is the primary entry point for respiratory pathogens, enhancing local immunity.
What role do T RM cells play in immunity?
T RM cells provide long-term protection by remaining in tissues and rapidly responding to reinfection.
How was the effectiveness of the vaccination assessed?
Effectiveness was assessed by challenging vaccinated mice with virulent mycobacteria and measuring immune responses.
What are the implications of this research?
This research could lead to improved strategies for tuberculosis vaccination and better understanding of immune memory.
Executive Industry Relevance
Intranasal BCG immunization in mice establishes a preclinical model for evaluating mucosal vaccine strategies against intracellular pathogens. The model enables assessment of lung-resident memory T cell generation and functional antibody-mediated protection, supporting target validation for tuberculosis and related infectious disease programs. This approach provides mechanistic de-risking by linking immunization route to pulmonary immune correlates predictive of efficacy.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of mucosal immunization hypotheses and pathway clarification for pulmonary immunity.
- Operational Value: Supports functional target validation through measurement of effector T and B cell responses in lung tissue.
- Predictive Value: Links resident memory T cell formation to long-term protection, aiding portfolio triage of vaccine candidates.
Screening & Assay Development
- Scientific Value: Prepares validated biological systems for downstream assessment of antigen-specific immune responses.
- Operational Value: Standardizes intranasal delivery and challenge protocols for reproducible quantitative readouts.
- Scalability: Supports platform reuse for screening adjuvant or strain variants in tuberculosis vaccine development.
Translational & Preclinical Research
- Scientific Value: Models disease-relevant pulmonary immune responses to mycobacterial challenge.
- Operational Value: Provides continuity from discovery through preclinical validation via measurable cytokine and antibody outputs.
- Risk Mitigation: Informs risk-adjusted advancement decisions by correlating TRM cell activation with pathogen clearance.
Pipeline & Workflow Integration
The method integrates into early discovery workflows by enabling hypothesis testing of mucosal vaccine mechanisms and biological de-risking of pulmonary immune targets.
- Discovery Biology: Supports interrogation of immunization routes and clarification of lung-specific immune pathways.
- Screening: Delivers assay readiness through standardized intranasal administration and quantifiable immune cell tracking.
- Analytics: Generates measurable outputs including effector TRM cell localization, cytokine release, and antigen-specific antibody titers.
- Translational Research: Connects to preclinical continuity via lung-resident immune memory models predictive of protection.
- Enterprise Reuse: Establishes a reusable platform for evaluating mucosal vaccine candidates against respiratory pathogens.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in mucosal immunity, target validation of pulmonary immune pathways, reduction of mechanistic ambiguity in vaccine mechanisms.
- Operational Value: Standardization of dosing and challenge procedures, reproducibility across laboratories, scalability for cohort studies.
- Strategic Value: Improved go/no-go decisions based on immune correlates, capital efficiency in early screening, reduced late-stage biological risk in vaccine programs.
- Portfolio Impact: Risk-adjusted prioritization of vaccine candidates using TRM and antibody correlates as advancement criteria.
Implementation Considerations
- Requires expertise in murine immunology and infectious disease modeling.
- Dependent on biosafety level 2 infrastructure for handling live mycobacterial strains.
- Necessitates standardized anesthesia and intranasal delivery techniques across operators.
- Involves adaptation considerations when translating dosing volumes to different model systems or strains.
- Practical limitations include variability in inhalation efficiency and the need for precise volumetric control during administration.
Biopharma FAQs
Why does measuring lung-resident memory T cells matter for target validation?
Measuring lung-resident memory T cells (TRM) validates the functional quality of mucosal immunization by identifying long-lived effector populations in the tissue of pathogen entry. Their presence correlates with sustained protection upon challenge, providing a mechanistic readout for de-risking vaccine candidates. This supports target validation by linking immunization route to durable pulmonary immunity.
How does isolating the intranasal route as an independent variable fit the discovery pipeline?
Isolating the intranasal route as an independent variable enables direct comparison of mucosal versus systemic immunization in controlling for antigen dose and strain. This fits the discovery pipeline by clarifying how delivery method shapes immune compartmentalization, particularly in lung tissue. It supports hypothesis-driven screening of routes that maximize resident effector cell generation.
What do quantitative measurements of effector B cells and antibody titers enable?
Quantitative measurement of effector B cells and antigen-specific antibody titers enables assessment of humoral immunity magnitude and functionality following vaccination. These outputs help determine whether immunization promotes opsonizing antibodies that enhance phagocytic clearance of mycobacteria. Such data support go/no-go decisions by correlating humoral responses with pathogen control in challenge models.
Why do replication requirements matter for cross-functional collaboration?
Replication requirements ensure that observations of TRM cell localization and antibody-mediated clearance are consistent across experiments, builds confidence in the model’s reliability. Consistent results across cohorts allow immunology, pharmacology, and translational teams to align on immune correlates of protection. This standardization supports cross-functional decision-making in vaccine advancement.
What statistical analysis capabilities are required before implementing this model?
Before implementation, teams require statistical capabilities to compare immune cell frequencies, cytokine levels, and antibody titers between vaccinated and control groups using appropriate parametric or non-parametric tests. Analysis must account for variability in inhalation efficiency and biological replicates to detect significant differences in protection metrics. These capabilities are essential for validating whether observed immune responses meet predefined efficacy thresholds.
10:11
Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
Related Videos
0 Views
09:03
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Related Videos
0 Views
12:54
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
Related Videos
0 Views
08:18
Evaluation of Vaccine-Induced Immunity Against Bacterial Infection in a Mouse Model
Related Videos
0 Views
07:33
Intralymphatic Immunotherapy and Vaccination in Mice
Related Videos
0 Views
16:56
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
Related Videos
0 Views
08:00
Intubation-mediated Intratracheal (IMIT) Instillation: A Noninvasive, Lung-specific Delivery System
Related Videos
0 Views
10:39
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Related Videos
0 Views
06:32
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Related Videos
0 Views
08:52
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Related Videos
0 Views
Last updated: 1 August 2026